SCHEMBL473915

SCHEMBL473915

N#CCc1cccc(B(O)O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 9/20 1.00
LPL P06858 2/20 0.50
LIPG Q9Y5X9 2/20 0.50
MMP3 P08254 1/20 0.50
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
MGLL Q99685 2/20 0.42
FFAR1 O14842 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16510887 0.85 ENPP2 (0.74) ENPP2LPLLIPGMMP3KDM4E
SCHEMBL14120840 0.81 ENPP2 (0.69) ENPP2LPLLIPGKDM4EALDH1A1
SCHEMBL237972 0.79 ENPP2 (0.63) ENPP2MMP3KDM4ETDP1FFAR1
SCHEMBL5872608 0.77 ENPP2 (0.72) ENPP2LPLLIPGKDM4EALDH1A1
Benzene SCHEMBL5438521 0.77 ENPP2 (0.61) ENPP2MMP3KDM4EALDH1A1TDP1
SCHEMBL8832 0.75 ENPP2 (1.00) ENPP2LPLLIPGKDM4EALDH1A1
SCHEMBL363788 0.75 ENPP2 (0.60) ENPP2LPLLIPGMGLLKMT2A
SCHEMBL4374157 0.74 ENPP2 (0.58) ENPP2MMP3KDM4ETDP1FFAR1
SCHEMBL1233598 0.74 MMP3 (0.65) ENPP2MMP3KDM4EALDH1A1TDP1
SCHEMBL14120836 0.74 ENPP2 (0.67) ENPP2LPLLIPGKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP claimed
US-10611908-B2 Micelles for mucoadhesive drug delivery MCMASTER UNIVERSITY (CA) 2020-04-07 US claimed
US-20180265694-A1 Micelles for Mucoadhesive Drug Delivery MCMASTER UNIVERSITY (CA) 2018-09-20 US claimed
EP-3344232-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY Mcmaster University (CA) 2018-07-11 EP claimed
WO-2017035656-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY MCMASTER UNIVERSITY (CA) 2017-03-09 WO claimed
EP-4743453-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4703359-A1 IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-03-04 EP disclosed
EP-3762381-B1 BIVALENT AGENTS COMPRISING A SERINE THREONINE KINASE (AKT) LIGAND COVALENTLY LINKED TO A DEGRADATION/DISRUPTION MOIETY FOR THE TREATMENT OF CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2025-05-07 EP disclosed
WO-2025015178-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
WO-2024222712-A1 IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-31 WO disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 US disclosed
US-6294573-B1 FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION ABBOTT LABORATORIES 2001-09-25 US disclosed
US-6288261-B1 DRUGS FOR INHIBITION OF ENZYMES ABBOTT LABORATORIES 2001-09-11 US disclosed
US-6235786-B1 RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS ABBOTT LABORATORIES 2001-05-22 US disclosed
WO-2000037433-A1 INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 2000-06-29 WO disclosed
EP-1001930-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 2000-05-24 EP disclosed
WO-1999006361-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases MMP1, MMP9, MMP3 ENPP2 626/4885LPL 1828/4885LIPG 2374/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE ENPP2 128/4885LPL 606/4885LIPG 25/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP ENPP2 1619/4885LPL 1994/4885LIPG 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.